Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Sadashiva Karnik, PhD

Sadashiva Karnik, Ph.D.

Appointed: 1997

No Patient Satisfaction Reviews
Sadashiva Karnik, PhD
Department: Molecular Cardiology
Location: Cleveland Clinic Main Campus
Mail Code NB50
9500 Euclid Avenue
Cleveland, OH 44195
Type of Doctor:

Biographical Sketch

Sadashiva S. Karnik, PhD, MSc, is a Professor in the Department of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland. He is also full staff in the Department of Molecular Cardiology at Cleveland Clinic's Research Institute and is adjunct professor of chemistry and biology, Cleveland State University, Cleveland. Dr. Karnik joined Cleveland Clinic in 1990 after serving as a research associate at the Massachusetts Institute of Technology (MIT), Cambridge, Mass.


Dr. Karnik graduated with a master’s of science degree from Kasturba Medical College, Manipal, India, and PhD in molecular genetics from the Indian Institute of Science, Bangalore, India. Dr. Karnik also completed post-doctoral work in molecular genetics at University of Zurich, Zurich, Switzerland.


A researcher with nearly 80 published papers to his credit, Dr. Karnik earned a National Merit Scholarship from the Government of India from 1969 to 1976. He has won many research awards, landed numerous grants and given lectures worldwide. In 2006, Dr. Karnik was a visiting professor and national lecturer for the Japanese Hypertension Society, Tokyo.

Professional Highlights

  • Establishing the relationship of extracellular cysteine connectivity and high-affinity state of GPCRs.
  • Delineating binding sites for hormone and antihypertensive agents on AT1 receptor
  • Constitutive activity of angiotensin receptors
  • Novel gene regulatory mechanisms activated by angiotensin receptors

Education & Fellowships

Doctorate - Indian Institute of Science
Bangalore India
Undergraduate - S.P. College of Sciences
Srinagar India
Fellowship - Massachusetts Institute of Technology
Cambridge, MA USA
Fellowship - University of Zurich Institute for Molecular Biology

Specialty Interests

Cardiac Hypertrophy, Hypertension, Renin-angiotensin System

Awards & Honors

  • 1990-2007, Member of LRI Staff
  • 1992-1997, NIH RO1grant: Structure-function analysis of mammalian rhodopsin 
  • 1992-1994, Pfizer Educational Grant: Recombinant expression of human mast cell chymase 
  • 1997-2001, NHLBI RO1: Molecular Basis of AngII receptor functions  
  • 1999 Established Investigator award of the American Heart Association
  • Study Section Panel: 1996-2000
  • American Heart Association National; 1995-1998 Ohio Heart Association; 1996 Foundation Fighting Blindness (Ad-Hoc)
  • 2001-2002 Astra-Zeneca Basic Research Award
  • 2002-2006 NHLBI RO1: Molecular Basis of AngII receptor functions (renew for years 4-8) 
  • 2002-2006 NHLBI RO1: Mechanism of cell death in expressing AT2 Receptor
  • Ad-hoc reviewer for NIH Experimental Cardiovascular Sciences Study Section, National Science
  • Foundation Reviewer Panel. NIH Vascular Cell Molecular Biology Study Section
  • Appointed to Committee on Appointments & Promotions LRI
  • Appointed Chair of Committee for LRI Retreat
  • Awarded Medal of the Tohoku Medical Society, Sendai, Japan
  • Invited Plenary Lecturer at 10th Tanabe Angiotensin Conference, Tokyo, Japan
  • 2004: Session Chair, Novel Aspects of AT2 receptor Signaling at the Angiotensin Gordon Conference-2004; Member, Organizing and Scientific Programs Committee, Angiotensin Gordon Conference
  • 2004 Appointed Professor, CCLCM
  • 2005-2009 Appointed Permanent Member, VCMB Study Section
  • 2006-2010 NHLBI RO1: Molecular Basis of AngII receptor functions (renew for years 9-12)
  • 2006-2011 NHLBI RO1: Phosphoproteomics and gene regulation 
  • 2006 Visiting Professor & National Lecturer at Japanese Hypt. Society, Tokyo, Japan
  • 2007 Reappointed to external advisory board COBRE II, University North Dakota School of Medicine

Additional Training

  • Post-doctoral Research Fellow: ETH-University of Zurich, Switzerland
  • Research Associate, Mass. Inst. Technology, Cambridge, MA USA


  • American Association for Advancement of Science
  • High blood Pressure Council of American Heart Association
  • American Chemical Society

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 3/1/2016, Dr. Karnik has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English